Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Other Financing Activities
Financing cash flows not reported separately.
Doximity, Inc.NYSE: DOCS
Other Financing Activities · Q2 FY2027 · quarter ended Sep 2026
Other financing activities growth accelerates
Q2 FY2027 other financing activities of $64.24M (cash outflow) rose 411.2% year over year, ahead of the +99.0% change in trailing-twelve-month other financing activities. Sequentially, it rose 435.4% from the prior quarter.
Context
- Other financing activities amounted to 7.1% of revenue in FY2026, up 1.2 pp from a year earlier.
- Other financing activities increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +411.2% holds above the trailing-twelve-month pace of +99.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2026
- (46.09M) USD
- Year-over-year change
- -35.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | (46.09M) | -35.0% |
| FY2025 | 2025-03-31 | (34.15M) | -914.6% |
| FY2024 | 2024-03-31 | 4.19M | -61.4% |
| FY2023 | 2023-03-31 | 10.86M | +18.0% |
| FY2022 | 2022-03-31 | 9.21M | — |
Other Financing Activities vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's LTM Sep 2026 other financing activities of $92.59M is the 6th largest of the 10 companies compared; the peer median is $2.21M.
- Its year-over-year change of +99.0% is the 9th highest of 10, against a peer median of +483.2%.
- Other financing activities amounts to 14.0% of revenue for DOCS, versus a peer median of 0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $646.8M | +524.3% | +54.0% | 15.3% | |
| LTM Jun 2026 | $639.9M | +1140.1% | — | 10.3% | |
| LTM Sep 2026 | $282.06M | +866.3% | -30.2% | 22.1% | |
| LTM Sep 2026 | $133.42M | +205.2% | +101.0% | 8.8% | |
| LTM Jun 2026 | $132.3M | +127.3% | +129.2% | 0.9% | |
| LTM Sep 2026 | $92.59M | +99.0% | — | 14.0% | |
| LTM Jun 2026 | $21M | +138.2% | — | 0.3% | |
| LTM Jul 2026 | $2.21M | +844.4% | +71.0% | 0.1% | |
| LTM Jun 2026 | $1.07M | -91.4% | +229.7% | 0.0% | |
| LTM Jul 2026 | $751K | +483.2% | — | 0.1% | |
| Peer median (excluding DOCS) | $2.21M | +483.2% | +86.0% | 0.9% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 154.78M | 112.82M | 147.58M | 223.19M | 196.05M |
| Depreciation & Amortization | 5.04M | 10.28M | 10.27M | 10.66M | 14.38M |
| Deferred Income Tax | (41.25M) | 13.23M | (8.59M) | (11.59M) | 32.14M |
| Stock-Based Compensation | 31.44M | 47.83M | 51.08M | 72.39M | 121.63M |
| Change in Working Capital | (40.33M) | (21.03M) | (24.52M) | (24.1M) | (45.7M) |
| Accounts Receivables | (31.02M) | (26.24M) | 3.99M | (27.21M) | (16.88M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 8.66M | (195K) | 8.33M | (663K) | 4.27M |
| Other Working Capital | (17.98M) | 5.4M | (36.85M) | 3.77M | (33.09M) |
| Other Non-Cash Items | 16.89M | 16.47M | 8.29M | 2.72M | 7.96M |
| Operating Cash Flow | 126.58M | 179.6M | 184.1M | 273.27M | 326.46M |
| Capital Expenditures | (5.7M) | (6.18M) | (5.8M) | (6.53M) | (8.96M) |
| Acquisitions (Net) | 0 | (53.5M) | 0 | 0 | (26.53M) |
| Purchases of Investments | (1.32B) | (190.56M) | (472.87M) | (675.56M) | (389.16M) |
| Sales of Investments | 681.72M | 190.32M | 509.85M | 652.78M | 571.82M |
| Other Investing Activities | 595K | 0 | (5.65M) | 0 | 0 |
| Investing Cash Flow | (640.57M) | (59.92M) | 31.19M | (29.3M) | 147.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 553.91M | 0 | 0 | 23.3M | 13.68M |
| Common Stock Repurchased | (2.7M) | (85.32M) | (280.72M) | (120.29M) | (431.65M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.21M | 10.86M | 4.19M | (34.15M) | (46.09M) |
| Financing Cash Flow | 560.42M | (74.46M) | (276.52M) | (131.14M) | (464.06M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 46.42M | 45.22M | (61.24M) | 112.83M | 9.56M |
| Free Cash Flow | 120.88M | 173.42M | 178.3M | 266.74M | 317.5M |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.